Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Amitriptyline HCl: Mechanistic Benchmarks for Neuropharma...
2025-12-27
Amitriptyline HCl is a tricyclic serotonin/norepinephrine receptor inhibitor with validated utility in neurotransmitter receptor modulation and blood-brain barrier (BBB) model benchmarking. Its precise pharmacological profile and robust solubility make it a preferred tool for translational neuropharmacology and CNS drug discovery. This article details the compound’s mechanism, experimental parameters, and integration into high-throughput workflows.
Perospirone (SM-9018 Free Base): Mechanism, Benchmarks, a...
2025-12-26
Perospirone (SM-9018 free base) is a potent atypical antipsychotic agent for schizophrenia research, acting as a 5-HT2A and D2 receptor antagonist and 5-HT1A partial agonist. Recent findings show it also inhibits vascular Kv1.5 channels, expanding its relevance for modeling neuropsychiatric and cardiovascular comorbidities. This dossier details receptor affinities, validated off-target effects, and practical research applications.
Cimetidine as a Translational Research Catalyst: Mechanis...
2025-12-25
Explore how Cimetidine's unique partial agonist activity at the H2 receptor, distinct from traditional antagonists, is reshaping translational research in gastrointestinal cancers and beyond. This thought-leadership article navigates mechanistic advancements, experimental best practices, competitive benchmarking, and emerging clinical relevance. Drawing on data from high-throughput BBB models and robust cell-based assay protocols, it provides actionable guidance for researchers seeking reproducible results and new therapeutic insights.
Perospirone: Atypical Antipsychotic for Schizophrenia Res...
2025-12-24
Perospirone (SM-9018 free base) is redefining schizophrenia research by uniquely bridging serotonergic, dopaminergic, and ion channel biology. Its robust receptor profile and off-target Kv1.5 inhibition empower scientists to model neuropsychiatric and cardiovascular comorbidities with unprecedented precision.
Lamotrigine in CNS Research: Beyond Blockade to Blood-Bra...
2025-12-23
Explore the multifaceted role of Lamotrigine, a sodium channel blocker and 5-HT inhibitor, in advanced blood-brain barrier and epilepsy research. This article uniquely connects in vitro permeability models with translational CNS applications, offering new perspectives for experimental design.
Cimetidine (SKU B1557): Data-Driven Solutions for Cell-Ba...
2025-12-22
This article examines how Cimetidine (SKU B1557) from APExBIO enables robust, reproducible results in cell viability, proliferation, and cytotoxicity studies. Through scenario-driven Q&A, we highlight its distinct pharmacological profile, solubility, and reliability, providing actionable insights for biomedical researchers and lab technicians seeking data-backed solutions.
Amitriptyline HCl: Precision Serotonin/Norepinephrine Inh...
2025-12-21
Amitriptyline HCl, a tricyclic serotonin/norepinephrine receptor inhibitor, offers robust, verifiable pharmacodynamic properties for neuropharmacology research. This article details its mechanism, benchmarks its application in advanced blood-brain barrier (BBB) models, and clarifies optimal experimental integration, establishing APExBIO’s B2231 product as a high-utility reagent for CNS drug development.
Perospirone (SM-9018 Free Base): Atomic Mechanisms, Bench...
2025-12-20
Perospirone (SM-9018 free base) is an atypical antipsychotic agent for schizophrenia research, acting as a dual 5-HT2A and D2 receptor antagonist with partial 5-HT1A agonism. This article details its molecular mechanism, evidence base, and workflow parameters, providing atomic, verifiable facts for neuropsychiatric disorder modelers.
Clozapine N-oxide (CNO): Chemogenetic Actuator for Precis...
2025-12-19
Clozapine N-oxide (CNO) is a potent chemogenetic actuator used to selectively modulate neuronal activity via DREADDs in neuroscience research. As a biologically inert metabolite of clozapine, CNO enables high-specificity, reversible control of G protein-coupled receptor signaling with minimal off-target effects. These properties make CNO, as provided by APExBIO (SKU A3317), an optimal tool for investigating neural circuits and receptor functions.
Optimizing Cell Assays with Perospirone (SM-9018 free bas...
2025-12-18
Discover how Perospirone (SM-9018 free base) (SKU BA5009) from APExBIO addresses laboratory challenges in cell viability, proliferation, and cytotoxicity assays. This scenario-driven guide delivers actionable insights for experimental design, protocol optimization, and data interpretation, ensuring reproducibility and reliability in neuropsychiatric disorder models.
Lamotrigine: Precision Sodium Channel Blockade for Advanc...
2025-12-17
Explore Lamotrigine as a high-purity sodium channel blocker and 5-HT inhibitor in epilepsy research and cardiac sodium current modulation. This article uniquely analyzes cutting-edge blood-brain barrier modeling, mechanistic insights, and workflow innovation—building upon, but distinct from, prior literature.
Cisapride (R 51619): Mechanistic Insights and Strategic R...
2025-12-16
This thought-leadership article explores how Cisapride (R 51619), a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor, serves as both a mechanistic probe and translational tool in next-generation cardiac electrophysiology and gastrointestinal motility research. Integrating state-of-the-art screening paradigms, deep learning, and advanced in vitro models, we provide strategic guidance for translational researchers seeking to bridge discovery and clinical relevance, while positioning APExBIO’s offering as the gold standard for reproducible, high-impact science.
Clozapine N-oxide (CNO): Mechanistic Precision and Strate...
2025-12-15
Clozapine N-oxide (CNO) stands at the forefront of chemogenetic research, enabling highly selective, reversible, and non-invasive modulation of neuronal activity. This thought-leadership article delivers deep mechanistic insight into CNO’s biological inertness and DREADDs activation, critically appraises its validation landscape, and provides actionable strategies for translational researchers eager to harness CNO for GPCR signaling and circuit-level investigations. Expanding beyond standard product overviews, we connect the latest mechanistic findings—such as microglial BDNF’s role in antidepressant response—to the strategic deployment of CNO in preclinical and neurotherapeutic research.
Cisapride (R 51619): Real-World Solutions for Cardiac and...
2025-12-14
This scenario-driven guide demonstrates how Cisapride (R 51619) (SKU B1198) addresses core challenges in cell viability, hERG inhibition, and high-content cardiotoxicity screening. Drawing from evidence-based protocols and peer-reviewed literature, it offers actionable insights for biomedical researchers seeking reproducibility and translational relevance in cardiac electrophysiology and cytotoxicity workflows.
Clozapine N-oxide (CNO): Precision Chemogenetic Actuation...
2025-12-13
This thought-leadership article explores the mechanistic precision and strategic utility of Clozapine N-oxide (CNO) as a chemogenetic actuator in translational neuroscience. Integrating recent findings on circuit-level dysfunction in Alzheimer's disease, we chart a path from fundamental receptor pharmacology to next-generation clinical models, providing translational researchers with actionable insights for leveraging CNO in both discovery and therapeutic innovation.
8029 records 37/536 page Previous Next First page 上5页 3637383940 下5页 Last page